Shareholder Votes

ABERCROMBIE & FITCH CO /DE/ shareholders approved Elect the Nine Director Nominees Named in the Proxy Statement to Serve Until the 2027 Annual Meeting of Stockholders at the 2026-06-03 meeting.

“Proposal 1 – Elect the Nine Director Nominees Named in the Proxy Statement to Serve Until the 2027 Annual Meeting of Stockholders Votes For Votes Against Abstentions Broker Non-Votes Kerrii B. Anderson 37,742,958 559,242 23,938 3,024,501 Andrew Clarke 38,276,302 29,727 20,109 3,024,501 Susie Coulter 38,276,514 25,556 24,068 3,024,501 James A. Goldman 37,976,045 329,340 20,753 3,024,501 Fran Horowitz 38,281,561 24,673 19,904 3,024,501 Helen E. McCluskey 38,276,569 29,087 20,482 3,024,501 Arturo Nuñez 38,279,236 26,350 20,552 3,024,501 Kenneth B. Robinson 38,278,611 27,115 20,412 3,024,501 Nigel Travis 38,271,706 33,487 20,945 3,024,501”

Vita Coco Company, Inc. shareholders approved Advisory vote on executive compensation. at the 2026-06-03 meeting.

“Item 3 – Advisory vote on executive compensation.”

Vita Coco Company, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.

“Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Vita Coco Company, Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2029. at the 2026-06-03 meeting.

“On June 3, 2026, The Vita Coco Company, Inc. (the “Company”) held its Annual Meeting of Stockholders.”

Medicus Pharma Ltd. shareholders approved Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Commo at the 2026-06-03 meeting.

“Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Common Shares for every one post-consolidation Common Share, if the Board determines such a consolidation is necessary or desirable, including, without limitation, for the purpose of meeting any applicable stock exchange or regulatory requirements. Shareholder approval of this Proposal 3 required the affirmative vote of at least two-thirds of the votes cast by the shareholders present at the Meeting in person or by proxy: For Against Abstain Broker Non-Votes 26,729,776 2,335,461 N/A 1”

Medicus Pharma Ltd. shareholders approved Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorpo at the 2026-06-03 meeting.

“Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorporation of the Company (the "Articles") or the Business Corporations Act (Ontario): Name For Withhold Abstain Broker Non-Votes William L. Ashton 15,181,189 354,284 N/A 13,529,765 Dr. Raza Bokhari 15,068,465 467,008 N/A 13,529,765 Robert J. Ciaruffoli 15,186,431 349,042 N/A 13,529,765 Barry Fishman 15,189,646 345,827 N/A 13,529,765 Dr. Larry Kaiser 15,198,014 337,459 N/A 13,529,765 Patrick Mahaffy 15,193,804 341,669 N/A 13,529,765 Dr. Sara R. May 15,192,642 342,831 N/A 13,529,765 Hon. Cathy McMorris Rodgers 15,178,833 356,640 N/A 13,529,765 Ajay Raju 15,190,298 345,175 N/A 13,529,765”

Medicus Pharma Ltd. shareholders approved Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors to fix the auditors' remuneration and terms of engagement at the 2026-06-03 meeting.

“Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors (the "Board") to fix the auditors' remuneration and terms of engagement: For Withhold Abstain Broker Non-Votes 28,308,860 756,378 N/A 0”

BLUE OWL CAPITAL INC. shareholders approved Ratification of Appointment of KPMG LLP as Independent Registered Public Accounting Firm for 2026 Fiscal Year at the 2026-06-04 meeting.

“The proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s 2026 fiscal year was approved based on the following votes: FOR AGAINST ABSTAIN 6,073,218,752 980,718 516,886”

BLUE OWL CAPITAL INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.

“The nominees listed below were elected as Class II directors of the Company to serve for three-year terms expiring at the 2029 Annual Meeting of Stockholders once their respective successors have been duly elected and qualified or until their earlier resignation or removal, based on the following votes: FOR AGAINST ABSTAIN BROKER NON-VOTES Claudia Holz 5,762,013,618 182,494,922 173,156 130,034,660 Marc S. Lipschultz 5,796,875,813 147,628,704 177,179 130,034,660 Michael D. Rees 5,797,152,129 147,345,212 184,355 130,034,660”

PennyMac Financial Services, Inc. shareholders approved Approval, by non-binding vote, of the Company's executive compensation. at the 2026-06-03 meeting.

“Proposal 3: Approval, by non-binding vote, of the Company’s executive compensation. Votes For Votes Against Abstentions Broker Non-Votes 41,064,673 1,453,740 229,612 4,799,772”

PennyMac Financial Services, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.

“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 47,183,413 284,212 80,172 0”

PennyMac Financial Services, Inc. shareholders approved Election of ten (10) director nominees to serve on the Board, each for a one-year term expiring at the 2027 Annual Meeting of Stockholders. at the 2026-06-03 meeting.

“Proposal 1: The election of ten (10) director nominees to serve on the Board, each for a one-year term expiring at the 2027 Annual Meeting of Stockholders. Director Votes For Votes Against Abstentions Broker Non-Votes David A. Spector 42,462,444 206,197 79,384 4,799,772 Doug Jones 42,438,823 230,534 78,668 4,799,772 Sunil Chandra 42,549,151 117,584 81,290 4,799,772 Jonathon S. Jacobson 41,821,686 847,759 78,580 4,799,772 Patrick Kinsella 42,521,407 147,577 79,041 4,799,772 Anne D. McCallion 42,579,466 84,803 83,756 4,799,772 Farhad Nanji 42,403,072 227,802 117,151 4,799,772 Jeffrey A. Perlowitz 42,602,569 66,388 79,068 4,799,772 Lisa M. Shalett 41,744,791 641,606 361,628 4,799,772 Theodore W. Tozer 42,602,365 66,791 78,869 4,799,772”

KAISER ALUMINUM CORP shareholders approved Approval of the Amended 2021 Plan.

“4. Approval of the Amended 2021 Plan — The Company's stockholders approved the Amended 2021 Plan. The voting results were as follows: For Against Abstain Broker Non-Votes 13,595,325.653799 785,562.439006 16,307.413120 722.574.000000”

KAISER ALUMINUM CORP shareholders approved Ratification of selection of Deloitte & Touche LLP as independent registered public accounting firm for 2026.

“3. Ratification of the Selection of Independent Registered Public Accounting Firm - The Company's stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for 2026. The voting results were as follows: For Against Abstain 14,847,826.494528 251,817.441411 20,125.569986”

KAISER ALUMINUM CORP shareholders approved Advisory vote on executive compensation.

“2. Advisory Vote on Executive Compensation - The Company's stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 14,207,656.775510 171,450.243473 18,088.486942 722.574.000000”

KAISER ALUMINUM CORP shareholders approved Election of three Class I directors for terms expiring at the 2029 Annual Meeting.

“1. Election of Directors - The stockholders elected three Class I directors, each for a term expiring at the Company's 2029 Annual Meeting of Stockholders. Each received the affirmative vote of a majority of the votes cast at the 2026 Annual Meeting. The voting results were as follows: Nominee Name Votes For Votes Withheld Broker Non-Votes James D. Hoffman 13,600,788.963056 796.383000 722.574.000000 Glenda J. Minor 14,118,306.174456 278,865.788600 722.574.000000 Brett E. Wilcox 13,838,262.963056 558,909.000000 722.574.000000”

Amerant Bancorp Inc. shareholders approved Ratify the appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal 3: The proposal to ratify the appointment of RSM US LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 received the following votes: For Against Abstain Broker Non-Vote 27,002,896 17,990 14,599 ---”

Amerant Bancorp Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers (Say-on-Pay) at the 2026-06-02 meeting.

“Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers (“Say-on-Pay”). Say-on-Pay received the following votes: For Against Abstain Broker Non-Vote 23,349,064 361,733 45,915 3,278,773”

Amerant Bancorp Inc. shareholders approved Election of directors to serve until the 2027 annual meeting of shareholders at the 2026-06-02 meeting.

“Proposal 1: To elect directors to serve until the 2027 annual meeting of shareholders. Each nominee received the following votes: Nominee For Against Abstain Broker Non-Vote Odilon Almeida 23,313,655 424,739 18,318 3,278,773 Carlos Iafigliola 23,684,663 65,177 872 3,278,773 Erin D. Knight 23,507,527 240,238 8,947 3,278,773 Jack Kopnisky 23,526,368 220,601 9,743 3,278,773 Lisa Lutoff-Perlo 23,253,309 494,284 9,119 3,278,773 Gustavo Marturet M. 23,099,095 644,562 13,055 3,278,773 Patricia Morrison 23,663,389 84,203 9,120 3,278,773 John W. Quill 23,666,083 75,856 14,773 3,278,773 Ashaki Rucker 23,585,958 159,808 10,946 3,278,773 Oscar Suarez 23,501,329 245,640 9,743 3,278,773 Millar Wilson 15,336,523 8,386,819 33,370 3,278,773”

Sarepta Therapeutics, Inc. shareholders approved Ratification of KPMG as the Company's Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“Proposal 5: Ratification of KPMG as the Company ’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2026. The results of the vote were as follows: For Against Abstain 79,907,368 2,110,136 291,784”

Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Employee Stock Purchase Plan at the 2026-06-04 meeting.

“Proposal 4: Approval of the Company ’s 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP. The results of the vote were as follows: For Against Abstain Broker Non-Votes 67,098,699 532,525 61,783 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan at the 2026-06-04 meeting.

“Proposal 3: Approval of the Company ’s 2026 Equity Incentive Plan The stockholders approved the 2026 Plan. The results of the vote were as follows: For Against Abstain Broker Non-Votes 63,233,193 4,395,283 64,531 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.

“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2025. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes 45,185,398 22,373,065 134,544 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company’s board of directors as members of Class I for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non-Votes Douglas S. Ingram 66,812,593 827,973 52,441 14,616,281 Hans Wigzell, M.D., Ph.D. 56,984,756 10,663,180 45,071 14,616,281 Kathryn J. Boor, Ph.D. 63,915,239 3,722,626 55,142 14,616,281 Michael Chambers 65,892,431 1,752,077 48,499 14,616,281 Deirdre Connelly 53,419,881 14,213,242 59,884 14,616,281”

SOUNDTHINKING, INC. shareholders approved Ratification of the Appointment of Baker Tilly US, LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 at the 2026-06-03 meeting.

“Proposal 3 – Ratification of the Appointment of Baker Tilly US, LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 The Company’s stockholders approved Proposal 3. The voting results were as follows: Votes For Votes Against Abstentions 9,990,264 19,439 48,723”

SOUNDTHINKING, INC. shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2026-06-03 meeting.

“Proposal 2 – Advisory Vote on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved Proposal 2. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,778,374 2,741,809 12,744 3,525,499”

SOUNDTHINKING, INC. shareholders approved Election of Class III Directors at the 2026-06-03 meeting.

“Proposal 1 – Election of Class I Directors The Company’s stockholders approved Proposal 1. The voting results were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Ralph A. Clark 6,257,783 275,144 3,525,499 Marc Morial 5,689,914 843,013 3,525,499 Ruby Sharma 6,247,338 285,589 3,525,499”

Axalta Coating Systems Ltd. shareholders approved Approval of compensation of named executive officers for 2025 at the 2026-06-03 meeting.

“Say on Pay for 2025: Votes For Votes Against Broker Non-Votes Abstentions 175,746,487 2,013,619 5,087,439 114,945”

Axalta Coating Systems Ltd. shareholders approved Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm and auditor at the 2026-06-03 meeting.

“Appointment of PricewaterhouseCoopers LLP: Votes For Votes Against Abstentions 178,516,805 4,352,198 93,487”

Axalta Coating Systems Ltd. shareholders approved Election of nine directors at the 2026-06-03 meeting.

“Election of Nine Directors: Name Votes For Votes Withheld Broker-Non-Votes Jan A. Bertsch 175,398,682 2,476,369 5,087,439 William M. Cook 174,519,296 3,355,755 5,087,439 Tyrone M. Jordan 168,990,869 8,884,182 5,087,439 Deborah J. Kissire 174,557,043 3,318,008 5,087,439 Rakesh Sachdev 172,104,009 5,771,042 5,087,439 Samuel L. Smolik 176,344,625 1,530,425 5,087,439 Kevin M. Stein 176,832,476 1,042,574 5,087,439 Chris Villavarayan 177,247,432 627,618 5,087,439 Mary S. Zappone 176,084,028 1,791,022 5,087,439”

LendingClub Corp shareholders approved Management proposal to amend and restate the Company's Eighth Amended and Restated Certificate of Incorporation to remove supermajority voting requirements at the 2026-06-02 meeting.

“5. Management Proposal to Amend and Restate the Company’s Eighth Amended and Restated Certificate of Incorporation (Supermajority Voting) Votes For Votes Against Votes Abstained Broker Non-Votes 79,546,469 285,084 16,787 12,165,826 Under the Company’s Eighth Amended and Restated Certificate of Incorporation, this proposal required the affirmative vote of the holders of at least two-thirds of all outstanding shares of the Company’s stock to pass. Based on the votes set forth above, the management proposal to amend and restate the Company’s Eighth Amended and Restated Certificate of Incorporation to remove the supermajority voting requirements to amend the Company’s governing documents was approved.”

LendingClub Corp shareholders approved Management proposal to amend and restate the Company's Eighth Amended and Restated Certificate of Incorporation to phase in declassification of the Board of Directors at the 2026-06-02 meeting.

“4. Management Proposal to Amend and Restate the Company’s Eighth Amended and Restated Certificate of Incorporation (Declassification) Votes For Votes Against Votes Abstained Broker Non-Votes 79,600,856 227,738 19,746 12,165,826 Under the Company’s Eighth Amended and Restated Certificate of Incorporation, this proposal required the affirmative vote of the holders of at least two-thirds of all outstanding shares of the Company’s stock to pass. Based on the votes set forth above, the management proposal to amend and restate the Company’s Eighth Amended and Restated Certificate of Incorporation to phase in the declassification of the Company’s Board of Directors was approved.”

LendingClub Corp shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-02 meeting.

“3. Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstained Broker Non-Votes 91,696,689 288,782 28,695 N/A Based on the votes set forth above, the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved.”

LendingClub Corp shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-02 meeting.

“2. Advisory Vote on the Compensation of the Company’s Named Executive Officers Votes For Votes Against Votes Abstained Broker Non-Votes 76,277,173 3,432,891 138,276 12,165,826 Based on the votes set forth above, the advisory vote on the compensation of the Company’s named executive officers as set forth in the Company’s proxy statement was approved.”

LendingClub Corp shareholders approved Election of Kathryn Reimann, Scott Sanborn and Michael Zeisser as Class III directors at the 2026-06-02 meeting.

“1. Election of Directors Nominees - Class III Directors Votes For Votes Against Votes Abstained Broker Non-Votes Kathryn Reimann 78,322,887 1,513,807 11,646 12,165,826 Scott Sanborn 78,134,719 1,702,913 10,708 12,165,826 Michael Zeisser 76,604,666 3,231,868 11,806 12,165,826 Based on the votes set forth above, each Class III director nominee was elected to serve until the 2029 Annual Meeting of Stockholders or until his or her successor has been elected and qualified or his or her earlier death, resignation or removal.”

BIOMARIN PHARMACEUTICAL INC shareholders approved Approval of an Amendment to the 2017 Equity Incentive Plan at the 2026-04-07 meeting.

“Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: For Against Abstain Broker Non-Votes 158,561,867 5,480,380 152,003 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved the Plan Amendment.”

BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-04-07 meeting.

“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: For Against Abstain Broker Non-Votes 142,742,800 21,287,767 163,683 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.”

BIOMARIN PHARMACEUTICAL INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-04-07 meeting.

“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy Statement, received the following votes: For Against Abstain 170,867,335 4,850,526 95,431 Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2026.”

BIOMARIN PHARMACEUTICAL INC shareholders approved Election of Directors at the 2026-04-07 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. A total of 193,270,028 shares of common stock were entitled to vote as of April 7, 2026, the record date for the Annual Meeting. There were 175,813,292 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal. Proposal 1: Election of Directors Directors Elected For Against Abstain Broker Non-Votes Elizabeth M. Anderson 152,826,855 11,325,400 41,995 11,619,042 Barbara W. Bodem 162,832,241 796,989 565,020 11,619,042 Ian T. Clark 144,380,101 19,160,530 653,619 11,619,042 Athena Countouriotis 162,326,065 1,823,399 44,786 11,619,042 Willard Dere 161,112,606 2,973,541 108,103 11,619,042 Mark J. Enyedy 161,113,325 3,032,040 48,885 11,619,042 Alexander Hardy 163”

DENTSPLY SIRONA Inc. shareholders approved Approval of Amendment No. 2 to the Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) to increase the number of shares of the Company’s Common Stock issuable under the 2024 Plan by 15,000,000 shares. at the 2026-06-02 meeting.

“4. Approval of Amendment No. 2 to the Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) to increase the number of shares of the Company’s Common Stock issuable under the 2024 Plan by 15,000,000 shares.”

DENTSPLY SIRONA Inc. shareholders approved Approval, by non-binding advisory vote, of the Company’s executive compensation for 2025. at the 2026-06-02 meeting.

“3. Approval, by non-binding advisory vote, of the Company’s executive compensation for 2025.”

DENTSPLY SIRONA Inc. shareholders approved Ratification of appointment of Deloitte and Touche LLP as the Company’s independent registered public accountants for 2026. at the 2026-06-02 meeting.

“2. Ratification of appointment of Deloitte and Touche LLP as the Company’s independent registered public accountants for 2026.”

DENTSPLY SIRONA Inc. shareholders approved Election of twelve directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified. at the 2026-06-02 meeting.

“The annual meeting of stockholders (the “Annual Meeting”) of DENTSPLY SIRONA Inc. (the “Company”) was held on June 2, 2026. The following matters were voted upon at the Annual Meeting, with the results indicated: 1. Election of twelve directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified.”

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 at the 2026-06-04 meeting.

“Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 The Company’s stockholders approved the appointment by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by voting as follows: For Against Abstain 20,479,183 154,131 47,235”

ORTHOPEDIATRICS CORP shareholders approved Approval of an amendment to the 2024 Incentive Award Plan to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 at the 2026-06-04 meeting.

“Approval, of an amendment to the 2024 Incentive Award Plan ("Plan") to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 The Company's stockholders approved the amendment to the 2024 Incentive Award Plan by voting as follows: For Against Abstain Broker Non-Votes 18,545,409 272,115 35,490 1,827,535”

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers at the 2026-06-04 meeting.

“Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows: For Against Abstain Broker Non-Votes 15,953,457 2,859,793 39,764 1,827,535”

ORTHOPEDIATRICS CORP shareholders approved Election of Directors at the 2026-06-04 meeting.

“Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company’s 2029 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows: Name Votes For Votes Withheld Broker Non-Votes George S. M. Dyer 10,843,747 8,009,267 1,827,535 Kelly Fischer 18,535,024 317,990 1,827,535 David R. Pelizzon 18,056,773 796,241 1,827,535 Harald Ruf 18,077,260 775,754 1,827,535”

Rimini Street, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“Proposal 3: Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 82,071,095 28,489 25,007 –”

Rimini Street, Inc. shareholders approved Non-binding, advisory vote on the compensation of the Company’s Named Executive Officers (Say-on-Pay Vote) at the 2026-06-03 meeting.

“Proposal 2: Non-binding, advisory vote on the compensation of the Company’s Named Executive Officers, as further described in the 2026 Proxy Statement (Say-on-Pay Vote): For Against Abstain Broker Non-Votes 58,922,771 3,999,631 1,198,310 18,003,879”

Rimini Street, Inc. shareholders approved Election of three Class III director nominees at the 2026-06-03 meeting.

“Proposal 1: Election of three Class III director nominees to the Board of Directors of the Company, each to hold office until the 2029 annual meeting of stockholders and until his successor is elected and qualified: Nominee For Withheld Broker Non-Votes Seth A Ravin 63,184,115 936,597 18,003,879 Steven Capelli 54,716,977 9,403,735 18,003,879 Jay Snyder 55,340,702 8,780,010 18,003,879”